A new report from Evaluate Vantage looks at new approaches aiming to solve problems facing the current generation of genetic medicines.
Briefing documents show why the FDA should await more data on the ALS project, but will it bow to patient pressure?
With Ferring filed and Seres preparing to do so, regulators' views on microbiome approaches to C difficile will soon be heard.
Novel approaches including gene editing are creeping towards approval.
This year has yet to see a blockbuster-style deal, but prices remain punchy nevertheless.
The sellside expects the world’s leading medtech to be outpaced by its rivals. Divestments might allow the group to defy this destiny.
Big upcoming events include data from a trial of Pfizer’s oral antiviral Paxlovid in patients at risk of severe illness.
But the pipeline contains various approaches that are worth watching, with data from Abbvie possibly the next big event.
Stock leaps in early trade, but to justify its huge valuation the technology might have to improve.